Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Revelation Biosciences Inc (REVB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: REVB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -60.03% | Avg. Invested days 13 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.53M USD | Price to earnings Ratio - | 1Y Target Price 170.72 |
Price to earnings Ratio - | 1Y Target Price 170.72 | ||
Volume (30-day avg) 122575 | Beta 0.18 | 52 Weeks Range 2.36 - 45.44 | Updated Date 04/1/2025 |
52 Weeks Range 2.36 - 45.44 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -87.68 |
Earnings Date
Report Date 2025-03-20 | When Before Market | Estimate -10.32 | Actual -4.98 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -52.93% | Return on Equity (TTM) -264.85% |
Valuation
Trailing PE - | Forward PE 0.89 | Enterprise Value -4199739 | Price to Sales(TTM) 2.88 |
Enterprise Value -4199739 | Price to Sales(TTM) 2.88 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.02 | Shares Outstanding 905228 | Shares Floating 859179 |
Shares Outstanding 905228 | Shares Floating 859179 | ||
Percent Insiders 5.09 | Percent Institutions 6.81 |
Analyst Ratings
Rating 4 | Target Price 12.75 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Revelation Biosciences Inc
Company Overview
History and Background
Revelation Biosciences Inc. is a clinical-stage biopharmaceutical company focused on the development of immunomodulatory therapies. Founded in 2011, Revelation's history includes preclinical development, clinical trials, and public listing. The company is dedicated to harnessing the power of the immune system for prevention and treatment of disease.
Core Business Areas
- REVTx-99: Focuses on the prevention of influenza A virus infections.
- REVTx-300: Is being developed as a potential treatment for chronic kidney disease (CKD) and inflammatory bowel disease (IBD).
- REVTx-200: Is an immunomodulatory protein for inhaled delivery to treat or prevent respiratory viral infections.
Leadership and Structure
The company has a board of directors and an executive leadership team including the CEO, CSO, and CFO. Organizational structure includes departments for research and development, clinical operations, and finance.
Top Products and Market Share
Key Offerings
- REVTx-99: A nasal formulation aimed at preventing influenza A virus infections. Currently in clinical development. Market share is currently $0 as it is pre-revenue. Competitors include influenza vaccines from companies like GSK (GSK) and Sanofi (SNY).
- REVTx-300: A therapeutic in development for treating chronic kidney disease (CKD) and inflammatory bowel disease (IBD). Currently in clinical development. Market share is currently $0 as it is pre-revenue. Competitors will vary based on approved indications but could include companies like AbbVie (ABBV) in IBD.
- REVTx-200: An immunomodulatory protein for inhaled delivery to treat or prevent respiratory viral infections. Currently in clinical development. Market share is currently $0 as it is pre-revenue. Competitors include antivirals from companies like Pfizer (PFE).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and strong competition. Immunomodulatory therapies are an area of growing interest.
Positioning
Revelation Biosciences is a clinical-stage company aiming to address unmet needs in viral infections and inflammatory diseases through immunomodulation. Its competitive advantage lies in novel formulations and targeting specific immune pathways.
Total Addressable Market (TAM)
The TAM for influenza prevention and treatment of chronic diseases is substantial, potentially exceeding billions of dollars annually. Revelation's positioning depends on successful clinical trials and regulatory approvals, but if successful, it can address a significant portion of the TAM.
Upturn SWOT Analysis
Strengths
- Novel immunomodulatory technology
- Focus on unmet medical needs
- Strong preclinical data
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Small company size
Opportunities
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Expansion into new indications
Threats
- Failure in clinical trials
- Competition from established pharmaceutical companies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- GSK (GSK)
- Sanofi (SNY)
- Pfizer (PFE)
- AbbVie (ABBV)
Competitive Landscape
Revelation Biosciences is a small, early-stage company compared to the large pharmaceutical companies that dominate its target markets. Its success depends on clinical differentiation and strategic partnerships.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily measured by advancement of clinical programs and securing funding.
Future Projections: Future projections are highly dependent on clinical trial outcomes and regulatory approvals. Analyst estimates are limited given the early-stage nature of the company.
Recent Initiatives: Recent initiatives include ongoing clinical trials, strategic partnerships, and presentations at scientific conferences.
Summary
Revelation Biosciences Inc. is a high-risk, high-reward clinical-stage biotech focused on immunomodulatory therapies. Its success is contingent upon positive clinical trial results and securing sufficient funding. The company must successfully navigate the regulatory landscape and compete with established pharmaceutical giants. It needs to closely watch the clinical trails and burn rate as they will be pivotal.
Similar Companies
- GSK
- SNY
- PFE
- ABBV
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Press releases
- Industry reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Revelation Biosciences Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2020-11-17 | CEO & Director Mr. James M. Rolke | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.revbiosciences.com |
Full time employees 8 | Website https://www.revbiosciences.com | ||
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.